Loading patent…
AssigneeEastern Virginia Medical School
InventorsNeel K. Krishna, Kenji Cunnion
Estimating the term…
The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.
A method for regulating complement cascade proteins using Astroviridae family coat protein(s) and derivatives thereof.
A method for inhibiting complement-mediated tissue damage comprising administering astrovirus coat protein or derivatives thereof.
The method of claim 13, wherein the tissue damage is related to rheumatoid arthritis.
The method of claim 13, wherein the tissue damage is related to systemic lupus erythematosus.
The method of claim 23, wherein the ischemia-reperfusion injury results from stroke.
The method of claim 23, wherein the ischemia-reperfusion injury results from myocardial infarction.
The method of claim 26, wherein the tissue injury is further the result of hyperacute rejection.
The method of claim 26, wherein the tissue injury is further the result of graft versus host disease (GVHD).
A method for vaccinating against astrovirus infection, comprising administering coat protein or a derivative thereof.
The method of claim 34, wherein the vaccine is a purified astrovirus coat protein.
The method of claim 34, wherein the vaccine is a recombinant astrovirus coat protein.
A pharmaceutical composition comprising an astrovirus coat protein or derivatives thereof, and at least one pharmaceutically acceptable carrier, diluent, or excipient.
A method for treating hereditary angioedema (HAE) by administering astrovirus particles, coat protein, or derivatives thereof.
Dependencies are inferred from the claim text.